Fig. 1: Neutralizing SARS-CoV-2 antibodies can be autoreactive.
From: Do cross-reactive antibodies cause neuropathology in COVID-19?
a | A fraction of SARS-CoV-2-binding monoclonal antibodies that have been derived from patients with COVID-19 can cross-react with mammalian tissue antigens. b | Similarly, antibodies detected in cerebrospinal fluid from patients with COVID-19 can bind to vessel, muscular and neuronal autoantigens. c | Indirect immunofluorescence using mouse brain (and further organ) sections has demonstrated specific autoantibody binding. d | Potential implications of antibody cross-reactivity that require urgent research.
